Accuracy and Longitudinal Consistency of PET/MR Attenuation Correction in Amyloid PET Imaging amid Software and Hardware Upgrades

References

1. 1.↵
   1. Jagust WJ,
   2. Bandy D,
   3. Chen K, et al

   ; Alzheimer’s Disease Neuroimaging Initiative. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6:221–29 doi:10.1016/j.jalz.2010.03.003 pmid:20451870

   CrossRefPubMedWeb of Science
2. 2.↵
   1. McKay NS,
   2. Gordon BA,
   3. Hornbeck RC, et al

   . Neuroimaging within the Dominantly Inherited Alzheimer’s Network (DIAN): PET and MRI. bioRxiv 20222022.2003. 2025.485799 https://www.biorxiv.org/content/10.1101/2022.03.25.485799v1. Accessed, March 30, 2022.
3. 3.↵
   1. Sims JR,
   2. Zimmer JA,
   3. Evans CD, et al

   ; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023;330:512–27 doi:10.1001/jama.2023.13239

   CrossRefPubMed
4. 4.↵
   1. Budd Haeberlein S,
   2. Aisen PS,
   3. Barkhof F, et al

   . Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 2022;9:197–210

   CrossRefPubMed
5. 5.↵
   1. van Dyck CH,
   2. Swanson CJ,
   3. Aisen P, et al

   . Lecanemab in early Alzheimer’s disease. N Engl J Med 2023;388:9–21 doi:10.1056/NEJMoa2212948 pmid:36449413

   CrossRefPubMed
6. 6.↵
   1. Jang H,
   2. Liu F,
   3. Zhao G, et al

   . Technical note: deep learning based MRAC using rapid ultrashort echo time imaging. Med Phys 2018;45:3697–704 doi:10.1002/mp.12964

   CrossRefPubMed
7. 7.↵
   1. Shiri I,
   2. Ghafarian P,
   3. Geramifar P, et al

   . Direct attenuation correction of brain PET images using only emission data via a deep convolutional encoder-decoder (Deep-DAC). Eur Radiology 2019;29:6867–79 doi:10.1007/s00330-019-06229-1 pmid:31227879

   CrossRefPubMed
8. 8.↵
   1. Liu F,
   2. Jang H,
   3. Kijowski R, et al

   . Deep learning MR imaging-based attenuation correction for PET/MR imaging. Radiology 2018;286:676–84 doi:10.1148/radiol.2017170700 pmid:28925823

   CrossRefPubMed
9. 9.↵
   1. Chen Y,
   2. Ying C,
   3. Binkley MM, et al

   . Deep learning-based T1-enhanced selection of linear attenuation coefficients (DL-TESLA) for PET/MR attenuation correction in dementia neuroimaging. Magn Reson Med 2021;86:499–513 doi:10.1002/mrm.28689

   CrossRefPubMed
10. 10.↵
    1. Ladefoged CN,
    2. Hansen AE,
    3. Henriksen OM, et al

    . AI-driven attenuation correction for brain PET/MRI: clinical evaluation of a dementia cohort and importance of the training group size. Neuroimage 2020;222:117221 doi:10.1016/j.neuroimage.2020.117221

    CrossRefPubMed
11. 11.↵
    1. Gong K,
    2. Han PK,
    3. Johnson KA, et al

    . Attenuation correction using deep learning and integrated UTE/multi-echo Dixon sequence: evaluation in amyloid and tau PET imaging. Eur J Nucl Med Mol Imaging 2021;48:1351–61 doi:10.1007/s00259-020-05061-w

    CrossRefPubMed
12. 12.↵
    1. Gong K,
    2. Yang J,
    3. Kim K, et al

    . Attenuation correction for brain PET imaging using deep neural network based on Dixon and ZTE MR images. Phys Med Biol 2018;63:125011 doi:10.1088/1361-6560/aac763 pmid:29790857

    CrossRefPubMed
13. 13.↵
    1. Arabi H,
    2. Zeng G,
    3. Zheng G, et al

    . Novel adversarial semantic structure deep learning for MRI-guided attenuation correction in brain PET/MRI. Eur J Nucl Med Mol Imaging 2019;46:2746–59 doi:10.1007/s00259-019-04380-x pmid:31264170

    CrossRefPubMed
14. 14.↵
    1. Gong K,
    2. Yang J,
    3. Larson PEZ, et al

    . MR-based attenuation correction for brain PET using 3D cycle-consistent adversarial network. IEEE Trans Radiat Plasma Med Sci 2021;5:185–92 doi:10.1109/trpms.2020.3006844 pmid:33778235

    CrossRefPubMed
15. 15.↵
    1. Leynes AP,
    2. Ahn S,
    3. Wangerin KA, et al

    . Attenuation coefficient estimation for PET/MRI with Bayesian deep learning pseudo-CT and maximum-likelihood estimation of activity and attenuation. IEEE Trans Radiat Plasma Med Sci 2022;6:678–89 doi:10.1109/TRPMS.2021.3118325

    CrossRefPubMed
16. 16.↵
    1. Landau SM,
    2. Fero A,
    3. Baker SL, et al

    . Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015;56:567–74 doi:10.2967/jnumed.114.148981

    Abstract/FREE Full Text
17. 17.↵
    1. Jack CR, Jr.,
    2. Wiste HJ,
    3. Lesnick TG, et al

    . Brain beta-amyloid load approaches a plateau. Neurology 2013;80:890–96 doi:10.1212/WNL.0b013e3182840bbe

    Abstract/FREE Full Text
18. 18.↵
    1. Joshi AD,
    2. Pontecorvo MJ,
    3. Clark CM, et al

    ; Florbetapir F 18 Study Investigators. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med 2012;53:378–84 doi:10.2967/jnumed.111.090340 pmid:22331215

    Abstract/FREE Full Text
19. 19.↵
    1. Vandenberghe R,
    2. Van Laere K,
    3. Ivanoiu A, et al

    . 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319–29 doi:10.1002/ana.22068 pmid:20687209

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Brendel M,
    2. Hogenauer M,
    3. Delker A, et al

    ; Alzheimer’s Disease Neuroimaging Initiative. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage 2015;108:450–59 doi:10.1016/j.neuroimage.2014.11.055 pmid:25482269

    CrossRefPubMed
21. 21.↵
    1. Chen K,
    2. Roontiva A,
    3. Thiyyagura P, et al

    ; Alzheimer’s Disease Neuroimaging Initiative. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med 2015;56:560–66 doi:10.2967/jnumed.114.149732

    Abstract/FREE Full Text
22. 22.↵
    1. Smith AM,
    2. Obuchowski NA,
    3. Foster NL, et al

    . The RSNA QIBA profile for amyloid PET as an imaging biomarker for cerebral amyloid quantification. J Nucl Med 2023;64:294–303 doi:10.2967/jnumed.122.264031

    Abstract/FREE Full Text
23. 23.↵
    1. Zhang Y,
    2. Brady M,
    3. Smith S

    . Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001;20:45–57 doi:10.1109/42.906424

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Otsu N

    . A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern 1979;9:62–66 doi:10.1109/TSMC.1979.4310076

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Jenkinson M,
    2. Smith S

    . A global optimisation method for robust affine registration of brain images. Med Image Anal 2001;5:143–56 doi:10.1016/s1361-8415(01)00036-6 pmid:11516708

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Carney JP,
    2. Townsend DW,
    3. Rappoport V, et al

    . Method for transforming CT images for attenuation correction in PET/CT imaging. Med Phys 2006;33:976–83 doi:10.1118/1.2174132

    CrossRefPubMed
27. 27.↵
    1. Avants BB,
    2. Tustison NJ,
    3. Song G, et al

    . A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 2011;54:2033–44 doi:10.1016/j.neuroimage.2010.09.025 pmid:20851191

    CrossRefPubMed
28. 28.↵
    1. Fonov VS,
    2. Evans AC,
    3. McKinstry RC, et al

    . Unbiased nonlinear average age-appropriate brain templates from birth to adulthood. Neuroimage 2009;47:S102 doi:10.1016/S1053-8119(09)70884-5

    CrossRef
29. 29.↵
    1. Landau S,
    2. Jagust W

    . Florbetapir Processing Methods. Los Angeles: Alzheimer’s Disease Neuroimaging Institute; 2015.
30. 30.↵
    1. Albrecht DS,
    2. Sagare A,
    3. Pachicano M, et al

    . Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. Brain Behav Immun 2021;94:299–307 doi:10.1016/j.bbi.2021.01.010 pmid:33486003

    CrossRefPubMed
31. 31.↵
    1. Kolibash S,
    2. Minhas D,
    3. Lopresti B

    . Centiloid Level-2 Analysis of [18F] Florbetaben (FBB) and [18F] Florbetapir (FBP) PET Image Data using the ADNI Pipeline. Centiloid Level-2 Analysis of [18F] Florbetaben (FBB) and [18F] Florbetapir (FBP) PET Image Data using the ADNI Pipeline
32. 32.↵
    1. Catana C,
    2. Laforest R,
    3. An H, et al

    . A path to qualification of PET/MRI scanners for multicenter brain imaging studies: evaluation of MRI-based attenuation correction methods using a patient phantom. J Nucl Med 2022;63:615–21 doi:10.2967/jnumed.120.261881 pmid:34301784

    Abstract/FREE Full Text
33. 33.↵
    1. Bland MJ,
    2. Altman D

    . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;327:307–10 doi:10.1016/S0140-6736(86)90837-8

    CrossRefPubMed
34. 34.↵
    1. Koo TK,
    2. Li MY

    . A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 2016;15:155–63 doi:10.1016/j.jcm.2016.02.012 pmid:27330520

    CrossRefPubMed
35. 35.↵
    1. Liu Y,
    2. Chen A,
    3. Shi H, et al

    . CT synthesis from MRI using multi-cycle GAN for head-and-neck radiation therapy. Comput Med Imaging Graph 2021;91:101953 doi:10.1016/j.compmedimag.2021.101953

    CrossRefPubMed
36. 36.↵
    1. Chen KT,
    2. Izquierdo-Garcia D,
    3. Poynton CB, et al

    . On the accuracy and reproducibility of a novel probabilistic atlas-based generation for calculation of head attenuation maps on integrated PET/MR scanners. Eur J Nucl Med Mol Imaging 2017;44:398–407 doi:10.1007/s00259-016-3489-z

    CrossRefPubMed
37. 37.↵
    1. Klunk WE,
    2. Koeppe RA,
    3. Price JC, et al

    . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015;11:1–15.e11-14 doi:10.1016/j.jalz.2014.07.003

    CrossRefPubMed
38. 38.↵
    1. Chen CD,
    2. McCullough A,
    3. Gordon B

    ; DIAN-TU Study Team, et al. Longitudinal head-to-head comparison of (11)C-PiB and (18)F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-beta monoclonal antibodies in dominantly inherited Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2023;50:2669–82 doi:10.1007/s00259-023-06209-0 pmid:37017737

    CrossRefPubMed